Hester Biosciences acquires technology from ICAR to develop Brucella vaccine

Currently, the company already manufactures the conventional Brucella Abortus S19 vaccine and supplying to all the states in India.

Sep 23, 2020 04:09 IST India Infoline News Service

Hester Biosciences on Wednesday signed an agreement towards receiving the indigenously developed technology from ICAR-IVRI (Indian Council of Agriculture Research – Indian Veterinary Research Institute), for developing the Brucella Abortus S19 Delta Per vaccine.

Currently, the company already manufactures the conventional Brucella Abortus S19 vaccine and supplying to all the states in India. However, S19 Delta Per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced safety, immunogenicity, as well as assuring lifelong immunity with a single shot in calf-hood, said Hester in its regulatory filing.

Hester in a statement said, "With this vaccine, Hester hopes to reach new heights not only within India but also become a channel for immunizing cattle against Brucella, worldwide."

Brucella is a disease of economic importance worldwide. Not only does it impact cattle, sheep, goat and swine, but it also gets transmitted to human beings. Adding, Hester said, "Incidentally there is no vaccine available to protect humans against Brucella. The animals need to be protected to protect mankind."

Further, Hester said, "Immunization with Brucella vaccine also helps cattle to remain healthy, thereby improving their milk production."

The company expects to launch the Brucella Abortus S19 Delta Per vaccine in 18 months.

On Sensex, Hester stock finished at Rs1721.15  per piece up 0.62%.

Related Story